Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health, Daiichi Sankyo to Develop CDx for HER-2 NSCLC Drug

NEW YORK – Guardant Health said Tuesday that it has entered a strategic collaboration with Daiichi Sankyo to pursue regulatory approval of its Guardant360 CDx assay as a companion diagnostic for the pharma firm's HER-2 antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), for the treatment of patients with advanced metastatic non-small cell lung cancer.

Financial terms of the agreement were not disclosed.

Guardant360 CDx is already approved by the US Food and Drug Administration to provide comprehensive genomic profiling to guide treatment in all solid tumors, including NSCLC. It also has specific companion diagnostic approval to identify non-small cell lung cancer patients who may benefit from treatment with osimertinib (AstraZeneca's Tagrisso).

In a statement, Guardant CEO Helmy Eltoukhy said that the emergence of molecularly targeted cancer drugs, as well as tests like Guardant360 that identify the patients eligible for them, has already been "life-changing" for NSCLC patients with NSCLC, but therapies like Daiichi Sankyo's can address "an unmet medical need to help non-small cell lung cancer patients with HER2 mutations."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.